Smith+Nephew to showcase advanced Orthopaedic Reconstruction technologies for Robotics, Knees, Hips, and Shoulders at AAOS 2025

Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include:

Robotics: Optimizing and personalizing surgery

With CORIOGRAPH^◊ Pre-Op Planning and Modeling Services advanced technology and the CORI Surgical System's image-agnostic solution for robotic-assisted knee and computer-guided hip replacement procedures, Smith+Nephew offers a highly personalized approach for both surgeons and their patients. CORIOGRAPH's recent addition of support for hip procedures expands the platform's reach to provide advanced planning and simulation technology for THA. A defining feature of the technology is the ability to simulate a patient's functional activities of daily living (ADLs) specific to their anatomy.¹

Alongside these advancements, the CORI^◊ Digital Tensioner enhances the level of personalization in knee procedures by providing objective gap data for planning and execution of the procedure.^2-4 Now available for UKA, TKA, and Revision TKA, the CORI Digital Tensioner is designed to deliver accurate gap balance measurements with the CORI Surgical System for optimizing the surgical plan to align with each patient's unique soft tissue anatomy.

These cutting-edge technologies enable a highly personalized and tailored surgical approach with the CORI Surgical System, ensuring that patient-specific needs are met. Learn more by visiting the CORIOGRAPH  webpage here.

                                        

Hips: Best-in-class just got better

Smith+Nephew's new CATALYSTEM^◊ Primary Hip System is designed to address the evolving demands of primary hip surgery - including the increased adoption of anterior approach procedures. It features a triple-taper stem design with uniform proximal loading,⁵ and the reduced distal stem geometry and shorter lengths are ideal for anterior approach - and suitable for all approaches.⁶

Smith+Nephew's total hip arthroplasty (THA) portfolio was recently recognized in the latest annual report from the Australian Orthopaedic Association National Joint Replacement Registry. It highlighted the exceptional performance of proprietary OXINIUM^◊ (Oxidized Zirconium) on highly cross-linked polyethylene where the data indicated the combination has the highest survivorship rate (>94.1%) among all bearing combinations over a 20-year period for THA.⁷ Read the press release here.

Knees: Raising the bar in revisions

Smith+Nephew recently launched proprietary OXINIUM implant technology on the LEGION^◊ Hinged Knee (HK) System that delivers the durability of metals, the wear resistance of ceramics, and corrosion resistance better than both metal and ceramic.^8-14 Part of the LEGION Total Knee (TK) System, the LEGION HK System is designed to provide a natural range of motion with medial pivot, lateral roll back, and screw home. Since 2011, the LEGION HK System has enabled surgeons to transition intraoperatively from a constrained revision knee implant to a CoCr-hinged assembly. Learn more by visiting the LEGION HK webpage here.

AETOS^◊ Shoulder System: Elegant design. Elevated experience.

Smith+Nephew recently received 510(k) clearance from the FDA for a stemless anatomic total shoulder for the AETOS Shoulder System (AETOS Stemless). AETOS Stemless addresses the growing demand for anatomic total shoulder replacement with a small operating room footprint allowing for an efficient procedure.¹⁵ It is designed to maximize metaphyseal fixation and stability with an inlay collar, cruciate fins, and porous titanium coating to encourage biological fixation.^16,17 Learn more by visiting the AETOS webpage here.

To learn more about Smith+Nephew's advanced solutions for Orthopaedic Reconstruction, please visit our booth (#3729) at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in San Diego March 11-13, 2025 or visit wwww.smith-nephew.com.

 - ends –

 

 

Media Enquiries

Dave Snyder          +1 (978) 749-1440 

Smith+Nephew      [email protected]

 

References

1. Smith+Nephew 2020. Internal Report. EA/RECON/VISIONAIRE/001/v6.
2. Smith+Nephew 2022. Optimus TKA Tensioner Gap Assessment Verification Report. Internal Report. 10059269.
3. Smith+Nephew 2022. Tensioner KPC: Tensioner Calibration Check. Internal Report. TR100116, REV B.
4. Smith+Nephew 2022. CORI TENSIONER. 2020.04 Study Cases. Preliminary Analysis Report REV B.
5. Smith + Nephew 2024. Finite Element Analysis of the CATALYSTEM Hip Stem Design. Internal Report. OR-24-025
6. Smith + Nephew 2024. Surgeon Feedback on the CATALYSTEM Total Hip System. Internal Report.  CSD.REC.24.001
7. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) Hip, Knee & Shoulder Arthroplasty: 2024 Annual Report Adelaide; AOA, 2024:1–629. Available at: https://aoanjrr.sahmri.com/annual-reports-2024. Accessed December 11, 2024.
8. Sheth NP, Lementowski P, Hunter G, Garino JP. Clinical applications of oxidized zirconium. J Surg Orthop Adv. 2008;17(1):17-26.
9. Davidson JA, Mishra AK, Poggie RA. Friction and UHMWPE wear of cobalt alloy, zirconia, titanium nitride, and amorphous diamond-like carbon implant bearing surfaces. Poster presented at: 4th World Biomaterials Con1992; Berlin, FRG.
10. Hobbs L, Rozen V, Mangin S, Treska M. Oxidation Microstructures and Interfaces in the Oxidized Zirconium Knee. Int J Appl Ceram Technol. 2005.
11. Long M, Riester L, Hunter G. Nano-Hardness Measurements of Oxidized Zr.2.5Nb and Various Orthopaedic Materials. 1998.
12. Smith+Nephew 2010. Hip Simulator Wear Testing of XLPE Liners Against Oxidized Zr-2.5Nb and BIOLOX Delta Heads. Interal Report. OR-10-155
13. Smith+Nephew 2010. OR-10-155.
14. Smith+Nephew 2016. OR-16-127
15. Smith+Nephew 2023. AETOS Instruments & Trays.
16. Internal Report. ER-04-0990-0020 REV B
17. Pilliar RM. Cementless implant fixation—toward improved reliability. Orthopedic Clinics of North America. 2005;36(1):113-119

       

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 ((LSE:SN, NYSE:SNN). The terms ‘Group' and ‘Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

 

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

^◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

.